AB265. Association between MDM2 SNP309T>G polymorphism and the risk of bladder cancer: new data in Chinese population and an update meta-analysis

Abstract

BackgroundMDM2 is a mainly negative regulator of p53 tumor suppressor pathway. We aimed to investigate evaluate the association between MDM2 SNP309 polymorphism and bladder cancer risk.MethodsA total of 535 bladder cancer patients and 649 health controls were recruited for our study. MDM2 SNP309 T>G polymorphism was genotyped by PCR-LDR method. Logistic regression was used to analyze the relationship between the genotype and susceptibility of bladder cancer. Kaplan-Meier estimates and log rank test were obtained to analyze the association between the genotype and risk of recrudesce in NMIBC patients. A multivariable Cox proportional hazards model was fitted to identify independent prognostic factors. To further investigate the association, we conducted a meta-analysis including six studies.ResultsThe frequency of the MDM2 SNP309 T>G polymorphism showed no significant difference between cases and controls (all P>0.05). In the stratification analysis, the results showed that G allele carriers were prone to have a significant decrease in risk of low-grade bladder cancer (adjusted OR: 0.613, 95% CI: 0.427–0.881), and G-variant was associated with a significant reduced risk of recurrence in NMIBC patients with or without chemotherapy (P<0.05). The results of mate-analysis showed that G allele and GG genotype of MDM2 SNP309 polymorphism were significant associate with increased risk of bladder cancer in Caucasians (both P<0.05), and no association was observed in total populations and Asians (P<0.05).ConclusionsMDM2 SNP309T>G polymorphism has no influence on bladder cancer risk in Asians, but this SNP may be associated with genetic susceptibility of bladder cancer among Caucasians.